This Recent Biotech IPO Has The Right Story At The Right Time – And The Right Pattern

The author of today’s article notes that high-profile IPOs typically follow a pattern – and given this pattern, he is bullish on “a biotech stock that went public just under a month ago with a story that perfectly fits the times, and whose stock has followed exactly that pattern.” Specifically, this biotech has developed an artificial intelligence platform for the development of antibody-based therapies – a platform that was used in the development of a COVID-19 drug by Eli Lilly and which could see high demand in the inevitable future pandemics. For more, CLICK HERE.